NASACORT AQ SUMMARY
Triamcinolone acetonide, USP, the active ingredient in Nasacort├é┬« AQ Nasal Spray, is a corticosteroid.
Nasacort AQ Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 6 years of age and older.
Media Articles Related to Nasacort AQ (Triamcinolone)
Hay Fever (Allergic Rhinitis)
Source: MedicineNet Allergic Cascade Specialty [2015.08.18]
Title: Hay Fever (Allergic Rhinitis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/18/2015 12:00:00 AM
Children know best whether an allergy spray works for them
Source: Allergy News From Medical News Today [2016.03.08]
A recent 14-day study that compared the efficacy of an allergy spray in 304 children aged 6-11 years with seasonal allergic rhinitis showed that the result depended on who assessed symptoms...
Published Studies Related to Nasacort AQ (Triamcinolone)
The effect of an absorbable gelatin dressing impregnated with triamcinolone
within the olfactory cleft on polypoid rhinosinusitis smell disorders. 
function in patients who underwent sinus surgery... CONCLUSION: We suggest that application of triamcinolone at the olfactory cleft
Comparison of the efficacy of intralesional triamcinolone acetonide and
5-fluorouracil tattooing for the treatment of keloids. 
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the
Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study. [2011.11.23]
ABSTRACT: BACKGROUND: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular oedema experienced progressive loss of vision. Stabilization of the blood retinal barrier introduces a rationale for intravitreal triamcinolone treatment in diabetic macular oedema. This study is intended to compare the best corrected visual acuity (BCVA) and the macular oedema index (MEI) at 3 month of primary treatment for diabetic macular oedema between intravitreal triamcinolone acetonide (IVTA) and laser photocoagulation... CONCLUSIONS: IVTA demonstrates good outcome comparable to laser photocoagulation as a primary treatment for diabetic macular oedema at three months post treatment. TRIAL REGISTRATION: ISRCTN05040192 (http://www.controlled-trial.com).
Adding Triamcinolone to Endoscopic Ultrasound-Guided Celiac Plexus Blockade Does Not Reduce Pain in Patients With Chronic Pancreatitis. [2011.09.22]
BACKGROUND & AIMS: The efficacy of endoscopic ultrasound-guided celiac plexus blockade (EUS-CPB) for painful chronic pancreatitis (CP) is uncertain. Triamcinolone is often mixed with bupivacaine to lengthen the analgesic effect. We investigated whether addition of triamcinolone increases and lengthens pain relief compared with EUS-CPB with only bupivacaine... CONCLUSIONS: Triamcinolone does not increase pain relief or lengthen the effects of EUS-CPB. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Effects of intracameral triamcinolone and gentamicin injections following cataract surgery. [2011.07]
CONCLUSION: Intracameral injections of triamcinolone acetonide and gentamicin appear to be a promising treatment option for the control of post-operative inflammation following cataract surgery.
Clinical Trials Related to Nasacort AQ (Triamcinolone)
Intralesional Steroids in the Treatment of Alopecia Areata [Recruiting]
Alopecia areata is a common form of hair loss which reportedly occurs in up to 1. 7% of the
population at some time in their life. Alopecia areata is apparently triggered when the
individual's own immune system attacks hair follicles on the scalp or body resulting in hair
loss ranging from single patches on the scalp (patch type alopecia areata) to loss of every
hair on the scalp and body (alopecia universalis). Currently, there are limited treatment
options for alopecia areata and unfortunately, the treatments utilized have never been
rigorously tested in a placebo controlled trial.
Triamcinolone (Kenalog) is a steroid solution that has been used as treatment for alopecia
areata for over 50 years. It is administered via injection into the scalp and appears to
have some efficacy for patients with mild to moderate alopecia areata. We currently do not
have objective data on the frequency of occurrence of successful regrowth, the duration of
response or the incidence of side effects. In addition, there is disagreement between
clinicians regarding the dose of intralesional triamcinolone (IL TAC) that is considered
This study aims to determine the frequency of response to treatment with 3 concentrations of
IL TAC, 2. 5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of
side effects compared to treatment with placebo (sterile saline solution). After the 1st 6
months non or partial responders may be treated for 6 months with open label triamcinolone
at the dose deemed appropriate by the investigator.
We will also perform skin biopsies of the scalp and draw blood at selected time points in
order to examine the immunohistochemical/pathological response in scalp hair follicles and
the systemic circulation to treatment with IL TAC for alopecia areata.
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [Completed]
The study involves the enrollment of patients over 18 years of age with diabetic macular
edema involving the center of the macula who have not already been given maximal laser
Patients with one study eye will be randomly assigned (stratified by prior laser) with equal
probability to one of five treatment groups:
1. Focal laser photocoagulation (modified ETDRS technique)
2. Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
3. Anterior peribulbar injection of 20 mg triamcinolone
4. Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
5. Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
For patients with two study eyes (both eyes eligible at the time of randomization), the
right eye (stratified by prior laser) will be randomly assigned with equal probabilities to
one of the five treatment groups listed above. If the right eye was assigned to laser only,
then the left eye will be assigned to one of the four triamcinolone groups above with equal
probability (stratified by prior laser). If the right eye was assigned to receive
triamcinolone, then the left eye will receive laser only.
Triamcinolone acetonide will be the corticosteroid utilized in this study. The triamcinolone
acetonide preparation to be used is Kenalog. Kenalog is manufactured by Bristol Myers Squibb
and is approved by the Food and Drug Administration for intramuscular use for a variety of
indications. Peribulbar injections of Kenalog have been used for a wide variety of ocular
conditions, particularly uveitis and post-cataract extraction cystoid macular edema, for
Two different triamcinolone regimens will be assessed in the study: 40 mg injected
posteriorly and 20 mg injected anteriorly. There is no indication of which treatment regimen
will be better. Although the injection behind the eye is more common than the injection near
the front of the eye, the injection near the front of the eye has less risk of injuring the
eye. However, it is possible that the injection near the front of the eye may increase eye
pressure more frequently. Little is known about which of the two injections decreases
macular edema and improves vision more often.
Patients enrolled into the study will be followed for three years and will have study visits
1 month, 2 months, 4 months, 8 months and annually after receiving their assigned study
treatment. For the first 8 months of the study, patients should only be retreated with their
randomized treatment. However, if the patient's visual acuity has decreased by 15 letters or
more, then any treatment may be given at the investigator's discretion. After completion of
the 8-month visit, treatment is at investigator discretion.
The primary objective of this study is to obtain estimates of efficacy and safety outcomes
for each of the treatment groups. These estimates will provide a basis for the sample size
estimation and hypothesis generation in a phase III trial.
Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis [Recruiting]
It is currently unknown whether or not the improvement in pain and function related to a
"steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks
to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone
significantly affect improvement in shoulder pain 6 weeks after injection.
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) [Active, not recruiting]
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and
investigate whether changes in gene expression, or the expression of specific biomarkers,
are either predictive of response to bevacizumab or indicative of response.
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis [Active, not recruiting]
This study is designed to determine the safety and tolerability of a single microinjection
of triamcinolone acetonide (TRIESENCE«) into the suprachoroidal space (SCS) of patients who
have non-infectious uveitis.
Reports of Suspected Nasacort AQ (Triamcinolone) Side Effects
Tooth Loss (7),
Weight Decreased (7),
Dental Caries (7),
Nerve Injury (6),
Dental Plaque (6),
Cluster Headache (6),
AGE-Related Macular Degeneration (6),
Basal Cell Carcinoma (6),
Pleural Effusion (6), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Nasacort AQ has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Nasacort AQ review by 37 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || sinusitis|
|Dosage & duration:|| || 1 to 2 sprays per nostril per day (dosage frequency: 1x per day) for the period of regularly|
|Other conditions:|| || allergies, headaches, sinus stuffiness, frequent colds|
|Other drugs taken:|| || Sudafed otc, Semprex, Singulair|
|Benefits:|| || Nasacort AQ has proven to be extremely effective in controlling my nasal stuffiness and sinusitis related to allergies. Before use, it seemed my nose/sinuses were clogged on & off and made me much more susceptible to colds/flu--as much as 4 to 5 times per year & lasting 10 days to 2 weeks each round. I was miserable. Nasacort keeps my nasal passages open--it's a wonder!!|
|Side effects:|| || No side effects noticed.|
|Comments:|| || 1 to 2 sprays per nostril per day. I tried to limit to 1 spray per side per day & found is just as effective. This is on a regular, permanent basis to control allergies.|
Page last updated: 2016-03-08